The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.

Dow Jones biotech giant Amgen, along with fellow biotech stocks Gilead and Vertex, are due to report fourth-quarter earnings ...

Biotech stocks are in focus as analysts track upcoming clinical data and regulatory decisions in autoimmune and rare disease ...

Healthcare stocks rallied in 2025, breaking a two-year slump as investors chased steadier rates, better valuations, and ...

The biotech sector staged a robust comeback in 2025, with the Nasdaq Biotechnology Index climbing 33.8%. Although concerns about potential high tariffs initially hurt the industry, sentiment among ...

The volatile biotech industry has put up a strong performance in 2025 despite the uncertain macroeconomic environment. While the tariff saga hit the pharma/biotech industry earlier in the year, the ...

UBS gave its highest conviction calls for 2026, laying out its top stock picks across sectors. The bank is bullish on a wide variety of companies spanning several high-growth sectors. A few of its top ...

The investment bank said many companies faced thesis-changing Phase 3 readouts this year, with outcomes that could materially reshape valuations regardless of the broader macro backdrop. But UBS also ...

On December 24, Jared Holz of Mizuho joined ‘Power Lunch’ on CNBC to talk about how to play biotech moving into 2026. Holz noted that healthcare has become the top-performing sector over the last 3 ...